EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

B4GALT5 inhibits CD8 + T-cell response by downregulating MHC-I level through ERAD pathway in PDAC

Xin Xing, Shi-Qi Yin, Xia-Qing Li, Hui Li, Hong-Tai Ma, Aziguli Tulamaiti, Shu-Yu Xiao, Yu-Tong Liu, Hao Zhang, Zhigang Zhang, Yan-Miao Huo, Xiao-Mei Yang und 2 weitere

Journal for ImmunoTherapy of Cancer · 2025-05 · 13 (5) · e010908

DOI: 10.1136/jitc-2024-010908 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal for ImmunoTherapy of Cancer, online erschienen am 02.05.2025. Verfasst von Xin Xing und 13 weiteren Autor:innen. Beteiligte Einrichtung: Shanghai Fengxian District Central Hospital, School of Medicine, Anhui University of Science and Technology, Shanghai, China. Hauptthemen laut MEDLINE: CD8-Positive T-Lymphocytes, Galactosyltransferases, Carcinoma, Pancreatic Ductal, Pancreatic Neoplasms. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 50 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: EPA, Scientific Research Foundation of SUMHS, Innovative Research Team of High-level Local University in Shanghai.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Immune evasion is a crucial event in the progression of pancreatic ductal adenocarcinoma (PDAC). The identification of new immunotherapeutic targets may provide a promising platform for advancing PDAC treatment. This study aims to investigate the role of beta-1,4-galactosyltransferase-5 (B4GALT5) in immune evasion by pancreatic cancer cells and evaluate its potential as an immunotherapeutic target.

Methods

We conducted a comprehensive analysis using RNA sequencing data and tissue microarrays from patients with PDAC to investigate the association between B4GALT5 expression and patient prognosis. Using animal models, we further explored the impact of B4GALT5 on the quantity and activity of tumor-infiltrating CD8 + T cells. RNA sequencing and co-immunoprecipitation were used to explore the mechanism by which B4GALT5 regulates major histocompatibility complex (MHC-I) levels.

Results

Our study demonstrates that high expression of B4GALT5 in tumor cells is significantly associated with poor prognosis in patients with PDAC and reduced cytotoxic activity of tumor-infiltrating CD8 + T cells. Specifically, B4GALT5 suppresses MHC-I expression in tumor cells through the endoplasmic reticulum-associated degradation pathway, enabling them to evade immune surveillance by CD8 + T cells.

Conclusions

B4GALT5 impairs CD8 + T-cell recognition of tumor cells by regulating MHC-I levels, thereby promoting immune evasion. This makes B4GALT5 a highly promising immunotherapeutic target for improving the poor prognosis of patients with PDAC.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

CD8-Positive T-LymphocytesGalactosyltransferasesCarcinoma, Pancreatic DuctalPancreatic NeoplasmsHistocompatibility Antigens Class IHumansMiceAnimalsFemaleMaleDown-RegulationPrognosisCell Line, Tumor

Stichwörter der Autor:innen

ImmunotherapyMajor histocompatibility complex - MHCT cellTumor microenvironment - TME

Substanzen

GalactosyltransferasesHistocompatibility Antigens Class I

Autor:innen und Institutionen

  • Shanghai Fengxian District Central Hospital, School of Medicine, Anhui University of Science and Technology, Shanghai, China.
  • Shanghai University of Medicine and Health Sciences Affiliated Sixth People's Hospital South Campus, Shanghai, China.
  • State Key Laboratory of Systems Medicine for Cancer, Shanghai Cancer Institute, Ren Ji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China.
  • The First Hospital of Jilin University, Changchun, Jilin, China.
  • Department of Gastrointestinal Surgery, Renji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China.
  • Department of Biliary-Pancreatic Surgery, Ren Ji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China xlzhang@shsci.org yangyang201298@163.com xmyang@shsci.org huoyanmiao@126.com.

Förderung

  • EPA
  • Scientific Research Foundation of SUMHS
  • Innovative Research Team of High-level Local University in Shanghai
  • Key Medical Disciplines of Shanghai Municipal Health Commission
  • Natural Science Foundation of Shanghai

Zitieren

APA

Xing, X., Yin, S. Q., Li, X. Q., Li, H., Ma, H. T., Tulamaiti, A., Xiao, S. Y., Liu, Y. T., Zhang, H., Zhang, Z., Huo, Y. M., Yang, X. M., Yang, Y., & Zhang, X. L. (2025). B4GALT5 inhibits CD8 + T-cell response by downregulating MHC-I level through ERAD pathway in PDAC. Journal for ImmunoTherapy of Cancer, 13(5), e010908. https://doi.org/10.1136/jitc-2024-010908

Vancouver

Xing X, Yin SQ, Li XQ, Li H, Ma HT, Tulamaiti A, et al. B4GALT5 inhibits CD8 + T-cell response by downregulating MHC-I level through ERAD pathway in PDAC. Journal for ImmunoTherapy of Cancer. 2025;13(5):e010908. doi:10.1136/jitc-2024-010908

BibTeX
@article{Xing2025,
  author = {Xing, Xin and Yin, Shi-Qi and Li, Xia-Qing and Li, Hui and Ma, Hong-Tai and Tulamaiti, Aziguli and Xiao, Shu-Yu and Liu, Yu-Tong and Zhang, Hao and Zhang, Zhigang and Huo, Yan-Miao and Yang, Xiao-Mei and Yang, Yan and Zhang, Xue-Li},
  title = {B4GALT5 inhibits CD8 + T-cell response by downregulating MHC-I level through ERAD pathway in PDAC},
  journal = {Journal for ImmunoTherapy of Cancer},
  year = {2025},
  volume = {13},
  number = {5},
  pages = {e010908},
  doi = {10.1136/jitc-2024-010908}
}
Kostenlos starten →